|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma显示文摘BACKGROUND: Angiogenesis is known to be essential to the survival, growth, invasion, and metastasis of tumor cells. Vascular endothelial growth factor (VEGF) are an important angiogenic factor regulating tumor angiogenesis, but its significance and tumor pathologic features are un- clear in hepatocellular carcinoma (HCC). In the present study, we analyzed expression of tissue VEGF, alteration of microvascular density (MVD) in microvessel angiogenesis, development and metastasis of HCC, and level of serum VEGF in differential diagnosis of benign and malignant liv- er diseases. METHODS: Tumor specimens were prospectively collected from HCC patients undergoing resection. Total RNAs were extracted and the expression levels were detected from different parts of HCC tissues. The cellular distributions of VEGF and MVD of liver tumors and their paracancerous and distal cancerous tissues were investigated by streptavi- din peroxidase (S-P) immunohistochemistry, respectively. The VEGF levels of circulating blood and hepatoma tissues were measured by enzyme-linked immunosorbent assay. RESULTS: The incidence of VEGF expression was 63.9% in HCCs (23/36 cases), 78.3% in non-encapsulated HCCs (18/23), and 90.9% in HCCs with extrahepatic metastasis (10/11), respectively. The VEGF expression was tightly correlated with MVD (P <0.01). The MVD in HCC with metastasis, low differentiation or non-encapsulation was significantly higher than that in HCC with intact capsule, high differentiation, or no metastasis. No significant diffe- rence was found between VEGF, MVD, tumor size, and hepatitis virus infection. The level of total RNA in HCC tis- sues was significantly lower but the VEGF level significantly higher than those in paracancerous or distal cancerous ones (P<0.01). The abnormal expression levels of VEGF in sera of HCC patients were directly correlated with the me- tastasis and recurrence of tumors. CONCLUSION: The high expression of VEGF and abnor- mality of tissue MVD are useful predictors for vascular inva- sion and metastasis of liver tumors. | Deng-Fu Yao, Xin-Hua Wu, Yong Zhu, Gong-Sheng Shi, Zhi-Zhen Dong, Deng-Bing Yao, Wei Wu, Li-Wei Qiu and Xian-Yong Meng Nantong, China Research Center of Clinical Molecular Biology , Department of Pathology and Department of Gastroenterology , Affiliated Hos- pital of Nantong University Department of Diagnostics , and Institute of Neurosciences , Nantong University Nantong 226001, China | 2005 | Hepatobiliary & Pancreatic Diseases International2005，4，2： | 81 |
| 2 | Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients显示文摘AIM: To analyze the correlation between cytokineinduced killer (CIK) cells adoptive immunotherapy and cancer-related death in gastric cancer patients. METHODS: One hundred and fifty-six gastric cancer patients after operation at the Third Affiliated Hospital of Soochow University were enrolled in this study. Their clinical data including demographic characteristics, operation time, tumor size, pathological type and staging, tumor metastasis, outcome of chemotherapy or CIK cells adoptive immunotherapy, survival time or time of death were collected with a standard structured questionnaire. Kaplan-Meier method was used to estimate the median survival time, and the 2- and 5- year survival rates. Hazard risk (HR) and 95% confidence interval (95% CI) of CIK cells adoptive immunotherapy for gastric cancer were calculated using the two-stage time-dependent covariates Cox model. RESULTS: The survival time of gastric cancer patients was longer after CIK cells adoptive immunotherapy than after chemotherapy (χ 2 = 10.907, P = 0.001). The median survival time of gastric cancer patients was also longer after CIK cells adoptive immunotherapy than after chemotherapy (49 mo vs 27 mo, P < 0.05). The 2- and 5-year survival rates of gastric cancer patients were significantly higher after CIK cells adoptive immunotherapy than after chemotherapy (73.5% vs 52.6%, 40.4% vs 23.9%, P < 0.05). A significant difference was observed in the survival curve for patients who received CIK cells adoptive immunotherapy (0, 1-10, 11-25, and over 25 frequencies) (χ 2 = 14.534, P = 0.002). The frequencies of CIK cells adoptive immunotherapy were significantly related with the decreasing risk of death in gastric cancer patients after adjustment for sex and age of the patients, tumor stage and relapse (HR = 0.54, 95% CI: 0.36-0.80) when the first stage Cox model was used to define the subjects who remained alive beyond 36 mo as survivors. However, no correlation was observed between the frequencies of death in CIK cells adoptive immunotherapy and the risk of gastric cancer patients (HR = 1.09, 95% CI: 0.63-0.89) when the second stage Cox model was used to define the subjects who survived for more than 36 mo as survivors. CONCLUSION: The survival time of the gastric cancer patients treated with chemotherapy combined with CIK cells adoptive immunotherapy is significantly longer than that of the patients treated with chemotherapy alone and increasing the frequency of CIK cells adoptive immunotherapy seems to benefit patients more. | Jing-Ting Jiang, Chang-Ping Wu, Lu-Jun Chen, Xiao Zheng, Department of Tumor Biological Treatment, Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China Yi-Bei Zhu, Jing Sun, Xue-Guang Zhang, Key Laboratory of Stem Cell of Jiangsu Province, Institute of Biotechnology, Key Laboratory of Clinical Immunology of Jiangsu Province, Soochow University, Suzhou 215123, Jiangsu Province, China Yue-Ping Shen, Wen-Xiang Wei, Department of Medicine, Soochow University, Suzhou 215123, Jiangsu Province, China Bin-Feng Lu, Department of Immunology, University of Pitts- burgh School of Medicine, Pittsburgh, PA 15261, United States | 2010 | World Journal of Gastroenterology2010，16，48： | 82 |
| 3 | 瑞舒伐他汀治疗中国高胆固醇血症患者疗效和安全性的随机双盲多中心对照研究显示文摘目的评价瑞舒伐他汀治疗中国高胆固醇血症患者的疗效和安全性。方法采用随机、双盲、多中心研究。患者经6周筛选后符合 LDL-C≥4.14 mmol/L(160 mg/dl),<6.50 mmol/L(250 mg/dl)、TG<4.52 mmol/L(400 mg/dl)者以2:1随机接受瑞舒伐他汀10 mg/d 或阿托伐他汀10mg/d 治疗。12周后瑞舒伐他汀组 LDL-C 未达到 ATPⅢ治疗目标者,予瑞舒伐他汀20 mg 延续治疗8周。结果 304例进入随机治疗阶段,瑞舒伐他汀10 mg/d 组201例,阿托伐他汀10 mg/d 组103例。意向治疗人群290例,符合方案人群263例。瑞舒伐他汀组治疗12周后血 LDL-C 显著下降,下降幅度为45.6%,显著大于阿托伐他汀组的39.0%(P<0.001)。瑞舒伐他汀组患者 LDL-C 达标率也较阿托伐他汀组(78.0%比72.7%)有增高趋势,且在高危人群中优势更为明显(56.5%比35.0%),但差异未达到统计学意义。瑞舒伐他汀降低 TG(-22.8%)以及升高 HDL-C(+6.6%)和ApoA-1(+12.5%)的幅度与阿托伐他汀组差别无统计学意义(分别为-16.6%,+4.3%和+9.8%)。29例患者接受20 mg/d 瑞舒伐他汀延续治疗,22例完成治疗患者中10例(45.5%)LDL-C达标。研究中未发现药物相关的严重不良反应事件。结论本组研究显示瑞舒伐他汀10 mg 降低LDL-C 的疗效优于同等剂量的阿托伐他汀,治疗3个月安全性与之类似。 | Rosuvastatin Registration Clinical Trial Group.Cardiovascular Institute and Fu Wai Hospital,Peking Union Medical College and Chinese Academy of Medical Science,Beijing 100037,China | 2007 | 中华心血管病杂志2007，35，3： | 117 |
| 4 | 第二次中国临床血脂控制达标率及影响因素多中心协作研究显示文摘目的了解我国临床血脂控制的最新现状,指导临床血脂异常防治实践。方法在全国21家省部级医院和6家地县级医院中,查阅2004年1月1日至2006年2月28日间开始服调脂药物,且同一药物同一剂量维持≥2个月的2237名患者病例资料,依据美国2004年国家胆固醇教育计划(NCEP)成人治疗组第三次报告(ATPBⅢ)及《中国成人血脂异常防治指南》标准计算血脂控制达标率。结果 (1)在符合任一血脂防治建议/指南的药物起始治疗标准的2094例患者中,80%来自省部级医院,60%为60岁以上,57%有胆固醇升高,15%无血脂异常,68%合并冠心病等动脉粥样硬化性疾病,75%合并高血压,80%为高危和极高危患者,84%使用他汀类药物,83%采取了不同程度的饮食治疗。(2)依据美国2004年 NCEP ATPⅢ最新报告,总达标率为34%,低危组、中危组、中高危组、高危组和极高危组达标率分别为85%、78%、61%、3 1%和22%,差异有统计学意义(趋势性检验 P<0.001);依据我国新的《成人血脂异常防治指南》,总达标率为50%,低危组、中危组、高危组和极高危组达标率分别为91%、77%、49%和38%,组间差异及趋势性检验均有统计学意义(P<0.001)。(3)联合用药者达标率为51%,单用他汀类35%,贝特类23%,烟酸类24%,其他类28%,组间差异有统计学意义(P<0.001)。(4)对1808例服用他汀类药物患者的多元 logistic 回归分析表明,他汀类药物剂量(高剂量比低剂量,OR=1.72,95%CI:1.15~2.58)、危险分层(极高危比低危,OR=0.02,95%CI:0.01~0.03)、基线 LDL-C[每升高0.259 mmol/L(10 mg/dl),OR=0.83,95%CI:0.80~0.86]和性别(女性比男性,OR=0.77,95%CI:0.60~0.99)等是影响达标率的主要因素。结论我国目前调脂药物的应用对象发生了很大变化,调脂治疗的目的已不单纯是为了降低胆固醇。临床血脂控制状况与各防治指南要求相距仍甚远,特别是高危和极高危患者。要进一步改善我国临床血脂控制状况,药物种类、药物剂量、联合治疗和治疗性生活方式改变等多方面均需要进一步提高。 | The Collaborative Research Group for the Second Multi-center Survey of Clinical Management of Dyslipidemia in China | 2007 | 中华心血管病杂志2007，35，5： | 127 |
| 5 | 尿激酶治疗急性心肌梗塞多中心临床试验1406例总结显示文摘为观察尿激酶天普洛欣(UKTP)经静脉溶栓治疗急性心肌梗塞(AMI)的临床有效性及安全性。收集协作组148家医院1994年11月至1996年4月经静脉UKTP溶栓治疗AMI患者1406例,观察临床疗效、副作用及病死率等。其中124例行90分钟冠状动脉造影评价梗塞血管开通情况。结果:梗塞血管临床再灌注率为73.5%,90分钟冠状动脉造影血管开通率为72.6%,5周总病死率为7.8%(109/1406),轻度出血10.2%(143/1406),中重度出血0.43%(6/1406),脑出血0.50%(7/1406)。老年(>65岁)甚至高龄(>75岁)患者溶栓及距发病超过6小时者,其用药仍然安全有效,UKTP合适的用药剂量可能为150万U左右。结果提示UKTP治疗AMI安全有效。 | The collaborative study group for national multicenter clinical trial of urokinase thrombolytic therapy (Correspondence: Hu Dayi, Xu Zhimin. Beijing Red Cross Chao Yao Hospital, Beijing 100020) | 1997 | 中华心血管病杂志1997，25，3： | 139 |
| 6 | 不稳定性心绞痛、急性非Q波心肌梗死不同抗栓疗法的对比研究显示文摘目的 观察不同抗栓方案对急性冠状动脉综合征心脏事件、出血风险和预后的影响。方法 本研究为前瞻性、多中心、随机、开放试验 ,入选患者随机分为静脉滴注普通肝素组和皮下注射低分子量肝素组。入选对象为不稳定性心绞痛或非Q波心肌梗死 ,入选前 4 8小时以内至少有一次心绞痛发作 ,ST段无抬高。肝素 10 0IU/kg静注 ,续 10 0 0IU/h ,维持活化的部分凝血活酶时间 (APTT)或活化的全血凝固时间 (ACT)于正常的 1 5~ 2 0倍 ,连续 7日。低分子量肝素 0 4~ 0 6ml,每日两次皮下注射 ,连续 7日。主要观察终点 :随访治疗 3 0日内发生急性心肌梗死、心脏性或非心脏性死亡和药物治疗无法控制心绞痛 ,需行急性血运重建术。住院至少 7日 ,随访至治疗后 3 0日。结果 本研究共入选符合条件的患者 4 0 2例 ,两组在性别、年龄、心血管危险因素和心绞痛发作方面差异无显著性。治疗后 7日 ,两组用药期间平均胸痛发作次数差异无显著性 ,但肝素组有更多的患者需口服硝酸甘油缓解胸痛 ;病死率在低分子量肝素组较普通肝素组低 ,两组比较P值为 0 0 62 ,复合终点事件 (死亡、心肌梗死和紧急血管重建 )在低分子量肝素组明显下降。低分子量肝素组出血事件明显少于肝素组。治疗开始后 3 0日 ,低分子量肝素组死亡和复合终点事? | Clinical Collaborative Study Group of Low Molecular Weight Heparin (Correspondent: HU Dayi, XU Juntang. Beijing Red Cross Chaoyang Hospital, Beijing University of Medical Sciences, Beijing 100020, China) | 2000 | 中华心血管病杂志2000，28，1： | 172 |
| 7 | 中国进展期乳腺癌共识指南(CABC 2015)显示文摘在2013年出版的《首届中国进展期乳腺癌共识指南(草案)》(CABC1)的基础上,本指南进一步更新了进展期乳腺癌诊疗过程的一般原则、相关的定义、疗效的评估、不良反应的管理及不同治疗方法的基本策略等内容;专家组系统阅读国内外各种关于进展期乳腺癌的临床研究(包括回顾性的资料分析),整理并总结了各种相关指南,召开会议组织专家进行了多次讨论,将在循证医学基础上达成的专家共识整理成文,为从事乳腺癌专业的医生,尤其是以治疗进展期乳腺癌为主要专业的医生,提供参考。 | China Medical Women′s Association of Clinical Oncology | 2015 | 癌症进展2015，13，3： | 84 |
| 8 | Effects of glutamine on intestinal permeability and bacterial translocation in TPN-rats with endotoxemia显示文摘AIM: To evaluate the protective effect and mechanism ofglutamine on the intestinal barrier function in totalparenteral nutrition (TPN) rats with trauma or endotoxemia.
METHODS: To perform prospective, randomized andcontrolled animal experimentation of rats with surgicaltrauma, TPN and endotoxemia, thirty-four male, adultSprague Dawley rats were divided into four groups: control group (n=8), TPN group (n=9), trauma and endotoxemia group (LPS, n=8) and trauma plus endotoxemia supplemented with glutamine in TPN solution group (Gin.group, n=9). All groups except the control group were given TPN solutions in 7-day experimental period. For Gin group, 1 000 mg/kg/d of glutamine was added to TPN solution during day 1-6. On the 7th day all the animals were gavaged with lactulose (66 mg) and mannitol (50 mg)in 2 mi of normal saline. Then 24 h urine with preservative was collected and kept at -20 ℃. On day 8, under intraperitoneal anesthesia using 100 mg/kg ketamin, the intestine, liver, mesenteric lymph nodes and blood were taken for examination.
RESULTS: The body weight of LPS group decreased most among the four groups. The structure of small intestinal mucosa in TPN group, LPS group and Gln group showed impairments of different degrees, and the damage of small intestinal mucosa in Gln group was remarkably alleviated.The concentrations of interleukins in small intestine mucosa were lower (for IL-4 and IL-6) or the lowest (IL-10) in Gln group. The IgA level in the blood plasma and the mucosa of Gln group was the highest among all of the groups. The urine lactulose/mannitol test showed that the intestinal permeability in LPS group was lower than that in TPN group (P<0.001), but there was no difference between LPS group and Gln group. The rate of bacterial translocation in Gln group was lower than that in LPS group (P<0.02).
CONCLUSION: Prophylactic treatment with glutamine could minimize the increments of intestinal permeability and bacterial translocation caused by trauma and endotoxemia in rats treated with TPN. | Lian-An Ding Jie-Show Li Clinical College of Nanjing University Medical School,305 East Zhongshan Road,Nanjing 210002 Jiangsu Province,China | 2003 | World Journal of Gastroenterology2003，9，6： | 89 |
| 9 | Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis显示文摘AIM To observe the inhibition of antisenseoligonucleotides (asON) phosphorthioate to thetissue inhibitors metalloproteinase-1 (TIMP-1)gene and protein expression in the liver tissue ofimmunologically induced hepatic fibrosis rats.The possibility of reversing hepatic fibrosisthrough gene therapy was observed.METHODS Human serum albumin (HSA) wasused to attack rats, as hepatic fibrosis model, inwhich asONs were used to block the gene andprotein expressing TIMP-1. According to theanalysis of modulator, structure protein, codingseries of TIMP-1 genome, we designed fourdifferent asONs. These asONs were injected intothe hepatic fibrosis models through coccygealvein. The results was observed by RT-PCR formeasuring TIMP-1 mRNA expression,immunohistochemistry and in situ hybridizationfor collagen Ⅰ, Ⅲ, special staining of collagenfiber, and electron microscopic examination.RESULTS Hepatic fibrosis could last within 363days in our modified model. The expressinglevel of TIMP-1 was high during hepatic fibrosisprocess. It has been proved by theimmunohistochemical and the electronmicroscopic examination that the asONphosphorthioate of TIMP-1 could exactly expressin vivo. The effect of colchicine wasdemonstrated to inhibit the expressing level ofmRNA and the content of collagen Ⅰ, Ⅲ in theliver of experimental hepatic fibrosis rats.However, the electron microscopy research andthe pathologic grading of hepatic fibrosisshowed that there was no significant differencebetween the treatment group and the modelgroup (P>0.05).CONCLUSION The experimental rat model ofhepatic fibrosis is one of the preferable modelsto estimate the curative effect of anti-hepaticfibrosis drugs. The asON phosphorthioate ofTIMP-1 could block the gene and proteinexpression of TIMP-1 in the liver of experimentalhepatic fibrosis rats at the mRNA level. It ispossible to reverse hepatic fibrosis, and it isexpected to study a new drug of anti-hepaticfibrosis on the genetic level. Colchicine has verylimited therapeutic effect on hepatic fibrosis,furthermore, its toxicity and side effects areobvious. | Qing He Nie Yong Qian Cheng Yu Mei Xie Yong Xing Zhou Yi Zhan Cao The Center of Infectious Disease Diagnosis and Treatment of PLA,Tangdu Hospital,Forth Military Medical University,Xi’an 710038,Shaanxi Province,ChinaDr,Qing He Nie graduated from Qinghai Medical College as a doctor in 1983,got master degree at Beijing 302 Army Hospital in 1993,got doctor degree at the Third Military Medical University in 1998,engaged in postdoctoral research at the Fourth Military Medical University from 1998 to 2000,now an associate professor,specialized in clinical and experimental research of infectious diseases,had more than 90 papers published,coauthor of ten books,first author of one book. | 2001 | World Journal of Gastroenterology2001，7，3： | 73 |
| 10 | Analysis of in vivo patterns of caspase 3 gene expression in primary hepatocellular carcinoma and its relationship to p21^(WAF1) expression and hepatic apoptosis显示文摘AIM To detect the expression of caspase 3gene in primary human hepatocellular carcinoma(HCC)and investigate its relationship to p21WAF1gene expression and HCC apoptosis.METHODS In situ hybridization was employedto determine caspase 3 and p21WAF1expression inHCC.In situ end-labeling was used to detecthepatocytic apoptosis in HCC.RESULTS Twenty-one of 39(53.8%)cases ofHCC were found to express caspase 3transcripts,while 45.2% of HCC failed toexpress caspase 3.Non-cancerous adjacent livertissues showed more positive caspase 3(87.5%,7/8)as compared with HCC(P<0.05).The expression of caspase 3 is correlated withHCC differentiation,72.2%(13/18)ofmoderately to highly differentiated HCC showedcaspase 3 transcripts positive,while only 38.1%of poorly differentiated HCC harbored caspase 3transcripts(P<0.05).No relationship wasfound between caspase 3 expression and tumorsize or grade or metastasis,although 52.5%(5/8)of HCC with metastasis were caspase 3positive and a little higher than that with nometastasis(51.6%,P>0.05).Expression of caspase 3 alone did not affect the apoptosisindex(AI)of HCC.The AI was 7.12%o in caspase3-positive tumors(n=21),while in caspase 3-negative cases(n=18)6.59%0(P>0.05).Expression of caspase 3 clearly segregated withp21WAF1positive tumors as compared withp21WAF1-negative cases(16 of 23,69.6% versus5 of 16,31.3%)with statistical significance(P=0.017).In the cases with positive caspase 3and negative p21WAF1,the Al was found slightlyhigher,but with no statistical significance,thanthat with expression of p21WAF1and caspase 3(7.21‰ vs 6.98‰,P>0.05).CONCLUSION Loss of caspase 3 expressionmay contribute to HCC carcinogenesis,althoughthe expression of caspase 3 does not correlatewell with cell apoptosis in HCC.p21WAF1may bemerely one of the inhibitors which can reducecaspase 3 mediated cell apoptosis in HCCs. | Bao Hua Sun Jun Zhang Bao JǜWang Xi Ping Zhao You Kun Wang Zhi Qun Yu Dong Liang Yang Lian Jie Hao Department of Clinical Immunology,Tongji Hospital,Tongji Medical University,Wuhan 430030,Hubei Province,China | 2000 | World Journal of Gastroenterology2000，6，3： | 65 |
| 11 | 结核病临床诊治进展年度报告(2012年)(第一部分结核病临床诊断)显示文摘近一年来,国内外在结核病临床诊断方面取得了诸多进展,不少诊断新方法、新技术得以在临床上开展应用。在细菌学诊断方面,两种新技术包括等温微量热技术及爆轰纳米金刚石技术与传统的培养法相结合,提高了阳性检出率,具有速度快、敏感度和特异度高等优点。分子影像学在肺结核及肺外结核诊断中也取得了较大的进展。γ-干扰素释放试验在菌阴肺结核及肺外结核的诊断方面具有较大优势。2012年结核病分子生物学诊断仍集中在以核酸扩增为核心的检测技术上,而最引人注目的是Xpert Mtb/RIF技术,其在结核病和耐药结核病诊断中取得了丰硕的成果,在儿童结核病及Mtb与HIV双重感染的诊断方面也发挥了重要作用。RNA恒温扩增技术不仅可用于诊断结核病,还可用于疗效的监测。内镜介入诊断部分介绍了呼吸内镜在肺结核、气管支气管结核、纵隔淋巴结结核及胸膜结核诊断中的应用进展。其中支气管内镜超声引导下经支气管针吸活检术引起了国内外学者的极大关注,该方法以其操作技术简单、微创、定位准确、敏感度和特异度高,以及可重复性强等优势,在纵隔及肺门淋巴结结核的诊断中发挥了越来越大的作用。 | Chinese Antituberculosis Association of Clinic Society | 2013 | 中国防痨杂志2013，35，6： | 66 |
| 12 | Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018(English version)显示文摘Contents1. General guidelines for diagnosis and treatment of colorectal cancer2. Diagnostic principles for colorectal cancer2.1 Colorectal cancer screening of asymptomatic healthy population2.2 Basic diagnostic principles2.2.1 Colorectal cancer diagnosis2.2.2 Appendix on colorectal cancer imaging staging and diagnosis2.3 Principles of pathological diagnosis2.4 Staging. | Chinese Society of Clinical Oncology(CSCO)diagnosis and treatment guidelines for colorectal cancer working group Suzhan Zhang Jin Li Sanjun Cai Ruihua Xu Zhen Zhang | 2019 | Chinese Journal of Cancer Research2019，31，1： | 66 |
| 13 | Current treatment for liver metastases from colorectal cancer显示文摘The liver is the commonest site of distant metastasis ofcolorectal cancer and nearly half of the patients withcolorectal cancer ultimately develop liver involved duringthe course of their diseases. Surgery is the only therapythat offers the possibility of cure for patients with hepaticmetastatic diseases. Five-year survival rates after resectionof all detectable liver metastases can be up to 40 %.Unfortunately, only 25 % of patients with colorectal livermetastases are candidates for liver resection, while the othersare not amenable to surgical resection. Regional therapiessuch as radiofrequency ablation and cryotherapy may beoffered to patients with isolated unresectable metastasesbut no extrahepatic diseases. Hepatic artery catheterchemotherapy and chemoembolization and portal veinembolization are often used for the patients with extensiveliver metastases but without extrahepatic diseases, whichare not suitable for regional ablation. For the patients withmetastatic colorectal cancer beyond the liver, systemicchemotherapy is a more appropriate choice. Immunotherapyis also a good option when other therapies are used incombination to enhance the efficacy. Selective internalradiation therapy is a new radiation method which can beused in patients given other routine therapies Without effects. | Lian-Xin Liu Wei-Hui Zhang Hong-Chi Jiang Department of Surgery, the First Clinical College, Harbin Medical University, Harbin 150001, Heilongjiang Province, China | 2003 | World Journal of Gastroenterology2003，9，2： | 61 |
| 14 | Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma显示文摘BACKGROUND:Hepatocellular carcinoma (HCC) is characterized by a multi-cause,multi-stage and multi-focus process of tumor progression.Its prognosis is poor and early diagnosis is of utmost importance.This study was undertaken to investigate the dynamic expression of oncofetal antigen glypican-3 (GPC-3) and GPC-3 mRNA in hepatocarcinogenesis and to explore their early diagnostic value for HCC.METHODS:A hepatoma model was induced in male Sprague-Dawley rats with 0.05% 2-fluorenylacetamide and confirmed by hematoxylin and eosin staining and gamma-glutamyltransferase (GGT) expression.Total RNA was purified and transcribed into cDNA by reverse transcription.Fragments of the GPC-3 gene were amplified by nested RT-PCR,and confirmed by sequencing.GPC-3 was analyzed by immunohistochemistry,Western blotting or ELISA.RESULTS:Positive GPC-3 expression showed as brown granule-like staining localized in the cytoplasm.Histological examination of hepatocytes revealed three morphological stages of granule-like degeneration,atypical hyperplasia (precancerous),and cancer formation,with a progressive increase of liver total RNA and GGT expression.The incidence of liver GPC-3 mRNA and GPC-3,and serum GPC-3 was 100%,100% and 77.8% in the HCC group,100%,100%,and 66.7% in the precancerous group,83.3%,83.3%,and 38.9% in the degeneration group,and no expression in the liver or blood of the control group,respectively.There was a positive correlation between liver GPC-3 mRNA and total RNA level (r=0.475,P<0.05) or liver GPC-3 (r=1.0,P<0.001) or serum GPC-3 (r= 0.994,P<0.001).CONCLUSION:Abnormal oncofetal antigen GPC-3 and GPC-3 mRNA expression in hepatocarcinogenesis may be promising molecular markers for early diagnosis of HCC. | Research Center of Clinical Medicine,Affiliated Hospital of Nantong University,Nantong 226001,China (Yao M,Yao DF,Qiu LW,Wu W,Sai WL,Yang JL and Zhang HJ) Department of Oncology,Yancheng First People’s Hospital,Yancheng 224001,China (Bian YZ) Department of Oncology,Second Affiliated Hospital,Nanjing Medical University,Nanjing 210011,China (Zhang CG) | 2011 | Hepatobiliary & Pancreatic Diseases International2011，10，3： | 51 |
| 15 | 甘草酸制剂肝病临床应用专家共识显示文摘甘草酸制剂是当前肝病领域中用于抗炎保肝治疗的一线药物之一。追溯其历史,甘草酸制剂在20世纪40年代即应用于肝病的治疗,70年代开始有明确的科学性研究论述[1]。目前市场上已经出现甘草酸单铵、复方甘草酸苷、甘草酸二铵、甘草酸二铵脂质体及异甘草酸镁等多种形式的产品。随着研究的不断深入,学术界对甘草酸制剂在各类肝病中的临床应用已积累了较多的循证医学证据,国内外多部肝病相关指南也对甘草酸二铵脂质体及异甘草酸镁等多种形式的产品。 | Expert Committee on Clinical Application of Glycyrrhizin Preparation in the Treatment of Liver Diseases | 2016 | 临床肝胆病杂志2016，32，5： | 51 |
| 16 | 米索前列醇和PG05配伍米非司酮终止早孕的临床多中心随机比较试验显示文摘本研究为一项由十个单位参加的多中心临床试验,随机比较了三种用药方案:1.米非司酮25mgQ12h×5+PG051mg阴道塞药(组Ⅰ),2.米非司酮,同前十米索600μg(组Ⅱ),3.米非司酮200mg+米索600μg(组Ⅲ)终止早孕的安全性、有效性和可接受性。结果显示完全流产率为94.22%(913/969),其中组Ⅲ为91.50%,明显低于组Ⅰ(95.22%)和组Ⅰ(96.12%)(P=0.025);失败率为1.65%(16/969),其中组Ⅲ为3.52%,显著高于组Ⅰ(1.37%)、组Ⅱ(0%)(P=0.001);不完全流产率为2.89%(28/969),失访(结局不明)率为1.24%(12/969),三组间均无明显差异(P>0.05);自应用PG至孕囊排出时间,三组分别为3.06±1.65,2.81±2.75,3.21±1.61h(X±SD),组Ⅱ稍短于其他两组,其差异有统计学意义(P<0.05);阴道出血持续时间和转经时间无明显组间差异(P>0.05)。90%以上的对象均对药物流产方法表示满意。结果提示米索配伍米非司酮的安全性、有效性和可接受性令人满意;米非司酮低剂量多次给药与米索有较好的协同作用。 | He Chang-hai Gao Er-sheng Chen Jun-hang Gu Jiang Gui You-lnn and Cao Feng-zhen et al.(Collabrating Grou) for Clinical Study on Misoprostol to induce Abortion, Shanghai, 200032) | 1994 | 生殖与避孕1994，14，1： | 47 |
| 17 | Characteristics of Obesity and Its Related Disorders in China显示文摘Obesity is a medical condition with excess body fat accumulation to the extent which leads to serious health consequences.Abdominal obesity,also known as central obesity,refers to the presence of excess fat in the abdominal area.Obesity,especially abdominal obesity,contributes to many metabolic disorders including metabolic syndrome (MetS),type 2 diabetes (T2DM) and cardiovascular diseases (CVD).The incidence of obesity has increased dramatically in recent years worldwide.In China,more than one-third of adults are overweight or obese and 10%-20% of all adults are affected by MetS.The pathogenesis underlying the abdominal obesity remains unclear.The ultimate health outcome of obesity and its related metabolic disorders have prompted physicians to take aggressive treatments (lifestyle changes,pharmacological interventions and surgical therapies) before a serious consequence becomes clinically apparent.In this review,we discuss the prevalence,pathogenesis and clinic features of obesity in China. | WEI-PING JIA ,CHEN WANG,SHAN JIANG,AND JIE-MIN PAN Department of Endocrinology and Metabolism,Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,Shanghai Diabetes Institute,Shanghai Clinical Center of Diabetes,Shanghai 200233,China | 2010 | Biomedical and Environmental Sciences2010，23，1： | 46 |
| 18 | 结核病临床诊治进展年度报告(2012年)(第二部分 结核病临床治疗)显示文摘近一年来,国内外在结核病临床治疗方面也取得了不少进展,许多新药物、新方案、新疗法在临床中得到了应用与验证。2012年,抗结核新药研究最令人鼓舞的事件是贝达喹啉(bedaquiline,TMC207)已被美国FDA批准上市,并可用于治疗耐多药结核病。免疫治疗及治疗性疫苗在临床结核病中的研究也取得了一定的进展。一项采用经过热处理灭活的Mycobacterium indicus pranii(MIP)及糖皮质激素联合化疗治疗结核渗出性心包炎的国际多中心随机、双盲、安慰剂对照研究值得关注。本报告介绍了肝炎治疗性疫苗V5用于治疗结核病的一项随机、双盲、安慰剂对照Ⅱb期临床研究结果。呼吸内镜介入治疗方面主要集中在评估各种方法在结核病中的治疗价值;同时较为系统地介绍了《气管支气管结核诊断和治疗指南(试行)》中介入治疗方面的内容。在结核病外科治疗方面补充了骨结核外科治疗进展,尤其是脊柱结核手术治疗的新方式及其应用。抗结核治疗新方案在耐药结核病治疗中的应用也进行了深入的研究。结核病合并HIV感染的治疗也取得了较大的进展,包括Mtb与HIV双重感染的预防性抗结核治疗、结核病治疗、抗逆转录病毒治疗、抗结核药物与抗逆转录病毒治疗药物之间相互作用、临床治疗效果、治疗不良反应,以及免疫重建炎症综合征等7个部分内容。 | Clinic Society of Chinese Antituberculosis Association | 2013 | 中国防痨杂志2013，35，7： | 44 |
| 19 | 临床研究协调员(CRC)行业指南(试行)显示文摘随着中国药物临床研究事业的发展,临床研究协调员(CRC)作为新兴的行业,扮演着越来越重要的角色。目前国内尚无统一的行业管理标准与指南,严重影响了CRC行业的健康发展。基于此,中关村玖泰药物临床试验技术创新联盟/中国药物临床试验机构联盟起草制定了《临床研究协调员行业管理指南》,从CRC职业基本要求、培训、等级评估、工作要求、监督管理等方面规范了行业行为。 | Zhongguancun Jiutai Drug Clinical Trial Technology Innovation Association/Chinese GCP Association,China | 2015 | 药物评价研究2015，38，3： | 42 |
| 20 | Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer显示文摘BACKGROUND: Although a variety of tumor markers areavailable for diagnosis of pancreatic cancer, their sensitivityand specificity have not yet been ideal. The aims of thisstudy was to detect a panel of serum tumor markers and toevaluate their significance in the diagnosis and prognosis ofpancreatic cancer patients.METHODS: Eight serum tumor markers including AFP,CEA, CA-50, CA72-4, CA-125, CA153, CA19-9 and CA242were detected in 129 patients with pancreatic cancer by usingchemiluminescence immunoassay, immunofluorescence as-say and immunoradiometric assay, respectively. The levelsof these markers were compared in 99 patients with non-pancreatic malignant tumor, 63 patients with other benigndiseases, and 27 patients with pancreatic cancer after pan-createctomy.RESULTS: Among the 8 tumor markers, CA19-9, CA242,CA-50, and CA72-4 were more sensitive in the diagnosis ofpancreatic cancer. Parallel combined testing could increasethe diagnostic sensitivity to 89.2%, and serial combined exa-mination could increase the diagnostic specificity to 92.3%.The serum tumor markers levels were decreased significant-ly after radical tumor resection.CONCLUSIONS: Serum CA19-9, CA242, CA-50, andCA72-4 are the preferred tumor markers to be used in thediagnosis and follow-up of operated cases of pancreaticcancer. Testing of a panel of multiple serum tumor mark-ers may increase the sensitivity and specificity in the diag-nosis of pancreatic cancer. | Xiao-Ting Jiang, Hou-Quan Tao and Shou-Chun Zou Clinical Medical Laboratory and Depart-ment of Surgery , Zhejiang Provincial People’ sHospital, Hangzhou 310014 , China | 2004 | Hepatobiliary & Pancreatic Diseases International2004，3，3： | 35 |
您所在的机构暂未开通此部分的功能，请联系管理员